Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hellenic Oncology Research Group
With
University Hospital of Crete
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed NSCLC.
ECOG Performance Status 0-2.
No previous treatment with Docetaxel.
Measurable Disease.
Brain metastases that have been treated with radiotherapy should be stable and asymptomatic.
Adequate liver kidney and bone marrow function.
Patients must be able to understand the nature of this study and give written informed consent.
You may not be if
Active cardiac disease: unstable angina or onset of angina within last 3 months, myocardial infarction within 6 months, congestive heart failure \> class II, cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.
Women who are pregnant or lactating.
Unknown HIV, chronic hepatitis B or chronic hepatitis C infections.
Serious neurologic or psychiatric disease.
Second primary malignancy within the past 5 years, except nonmelanomas skin cancer or in situ carcinoma of the cervix.
Active uncontrolled infection.
Clareo Health | Docetaxel and Carboplatin Versus Docetaxel as Second Line Treatment in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)
